Cosentyx and quality of life for psoriasis patients.- Novartis.

Novartis announced additional results from the SCULPTURE study showing that two thirds of moderate to severe plaque psoriasis patients treated with Cosentyx (secukinumab) reported no impact of skin disease on their quality of life through 5 years, as described by the Dermatology Life Quality Index (DLQI) 0/1 response (72.7% at Year 1 and 65.5% at Year 5) - a questionnaire used to evaluate the impact of skin disease on a patient's quality of life. These data were presented at the 2018 American Academy of Dermatology (AAD) Annual Meeting in San Diego, California.

Study findings also show absolute PASI <=1><=2><=3 scores at year 1 58.6 67.9 and 74.1 respectively were sustained to year 5 53.3 66.4 and 75.4 respectively as observed analysis. absolute pasi scores can provide an indication of disease severity after treatment. achievement of an absolute pasi score lower than 2 or 3 has been proposed as an indication of treatment success. psoriasis is not simply a cosmetic problem but a persistent chronic long-lasting and sometimes distressing disease which can affect even the smallest aspects of peoples lives on a daily basis.>

"There is a link between achieving skin clearance and improved quality of life, and proper management of psoriasis should address both the physical symptoms of the disease and its impact on patients' daily lives," said Craig Leonardi, MD, Adjunct Professor of Dermatology at St. Louis University School of Medicine. "Results from the SCULPTURE study show treatment with Cosentyx can deliver both over the long-term. It's encouraging to see such improvements in DLQI responses and absolute PASI scores below 3 through 5 years." The most common adverse events included nasopharyngitis, upper respiratory tract infection and headache, consistent with those reported in the core study and previous Phase III studies.